$-0.28 EPS Expected for Cascadian Therapeutics (USA) (CASC); Last Week CBL & Associates Properties, Inc. (CBL) Coverage

October 12, 2017 - By Clifton Ray

Among 11 analysts covering CBL & Associates Properties (NYSE:CBL), 2 have Buy rating, 0 Sell and 9 Hold. Therefore 18% are positive. CBL & Associates Properties had 27 analyst reports since July 21, 2015 according to SRatingsIntel. The company was maintained on Friday, June 16 by Jefferies. The firm has “Neutral” rating given on Wednesday, January 6 by Goldman Sachs. On Monday, September 25 the stock rating was maintained by Jefferies with “Buy”. On Wednesday, August 30 the stock rating was maintained by Stifel Nicolaus with “Hold”. As per Wednesday, January 27, the company rating was initiated by Boenning & Scattergood. Citigroup upgraded the stock to “Neutral” rating in Monday, January 30 report. Stifel Nicolaus maintained it with “Hold” rating and $8.25 target in Friday, July 14 report. The company was maintained on Friday, February 5 by UBS. The firm has “Neutral” rating by Goldman Sachs given on Thursday, June 2. As per Friday, July 15, the company rating was upgraded by KeyBanc Capital Markets. See CBL & Associates Properties, Inc. (NYSE:CBL) latest ratings:

25/09/2017 Broker: Jefferies Rating: Buy New Target: $11.0 Maintain
30/08/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $8.25 Maintain
20/08/2017 Broker: Jefferies Rating: Buy New Target: $11.0 Maintain
07/08/2017 Broker: Boenning & Scattergood Rating: Hold Maintain
17/07/2017 Broker: Jefferies Rating: Buy New Target: $11.0000 Maintain
14/07/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $8.25 Maintain
16/06/2017 Broker: Jefferies Rating: Buy New Target: $11.0000 Maintain
23/06/2017 Broker: Barclays Capital Rating: Hold New Target: $9.00 Maintain
23/05/2017 Broker: Jefferies Rating: Buy New Target: $13.00 Maintain
05/05/2017 Broker: Hilliard Lyons Rating: Buy Maintain




Analysts expect Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) to report $-0.28 EPS on November, 6.They anticipate $0.26 EPS change or 48.15% from last quarter’s $-0.54 EPS. After having $-0.30 EPS previously, Cascadian Therapeutics Inc (USA)’s analysts see -6.67% EPS growth. The stock decreased 1.38% or $0.06 during the last trading session, reaching $4.28. About 643,637 shares traded or 46.07% up from the average. Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) has declined 30.85% since October 12, 2016 and is downtrending. It has underperformed by 47.55% the S&P500.

Investors sentiment increased to 1.8 in 2017 Q2. Its up 0.94, from 0.86 in 2017Q1. It improved, as 33 investors sold CBL & Associates Properties, Inc. shares while 43 reduced holdings. 53 funds opened positions while 84 raised stakes. 168.52 million shares or 12.00% more from 150.47 million shares in 2017Q1 were reported. Sentinel Communications Lba reported 502,562 shares stake. Global X Management Lc accumulated 867,144 shares. Cibc Asset reported 0% of its portfolio in CBL & Associates Properties, Inc. (NYSE:CBL). The Arizona-based Tci Wealth Advsr Inc has invested 0% in CBL & Associates Properties, Inc. (NYSE:CBL). Hsbc Holdings Pcl has invested 0% of its portfolio in CBL & Associates Properties, Inc. (NYSE:CBL). Dimensional Fund Advsr Lp, Texas-based fund reported 2.48M shares. Valley Natl Advisers owns 800 shares or 0% of their US portfolio. The New York-based Retail Bank Of Mellon has invested 0.01% in CBL & Associates Properties, Inc. (NYSE:CBL). Aqr Capital Mgmt Ltd Liability Co reported 158,076 shares stake. Ls Inv Advsr Ltd holds 0% of its portfolio in CBL & Associates Properties, Inc. (NYSE:CBL) for 6,205 shares. Teacher Retirement Of Texas holds 0.04% or 653,034 shares. Schroder Inv Group Inc reported 9,695 shares. 2,258 are owned by Advisory Limited Liability Company. 174,300 were reported by New York State Common Retirement Fund. Raymond James And Assoc reported 19,531 shares.

CBL & Associates Properties, Inc. is a self-managed, self-administered, integrated real estate investment trust. The company has market cap of $1.46 billion. The Firm owns, develops, acquires, leases, manages and operates regional shopping malls, open-air and mixed-use centers, outlet centers, associated centers, community centers and office properties. It has a 14.42 P/E ratio. The Company’s divisions are Malls, Associated Centers, Community Centers and All Other.

Since May 17, 2017, it had 2 insider purchases, and 0 selling transactions for $37,404 activity. 2,400 shares were bought by Curry Jeffery V., worth $17,688 on Wednesday, May 17. The insider Reinsmidt Kathryn A. bought 2,688 shares worth $19,716.

The stock decreased 1.63% or $0.14 during the last trading session, reaching $8.47. About 2.68 million shares traded. CBL & Associates Properties, Inc. (NYSE:CBL) has declined 23.94% since October 12, 2016 and is downtrending. It has underperformed by 40.64% the S&P500.

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The company has market cap of $216.37 million. The Firm focuses on the development of therapeutic products for the treatment of cancer. It currently has negative earnings. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor 2 inhibitor.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts